Answers are grounded in this paper and cite their sources.
This case of a middle aged woman with IL-12p40 deficiency and recurrent Mycobacterium kansasii infection demonstrates that in vitro sensitivities do not reliably predict the clinical response of non-tuberculous mycobacteria (NTMB), and emphasises the need to exercise caution when reducing treatment intensity in patients with type 1 cytokine defects on the basis of in vitro minimum inhibitory concentration (MIC) data alone.
No takes yet. Share an insight, caveat, or question.
Buckland et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: